Antimicrobial activity of latamoxef (moxalactam) against both bacteroides fragilis and escherichia coli in an intraperitoneal abscess model

Richard W. Harris, William L. Moore, J. Bruce Arensman, J. Peter Rissing

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The antimicrobial activity of latamoxef (moxalactam) was examined against Bacteroides fragilis and Escherichia coli individually and in combination in an intraperitoneal tissue capsule animal model during ten days of therapy given at 40 mg/kg/day. Mean peak serum concentration was 32.8 mg/1. Mean capsular latamoxef concentrations during samplings on days three, seven and ten were 1.8 mg/1 for Bact. fragilis, 0.7 mg/1 for E. coli, <0.5 mg/1 for polymicrobial infection and 3.4 mg/1 in uninoculated controls. Capsular colony counts for Bact. fragilis and E. coli monomicrobial infections decreased by 2.2 and 4.0 log10 cfu respectively and 1.9 and 3.6 log10 cfu in polymicrobial infections. Latamoxef concentrations necessary to eliminate viable bacteria in both monomicrobial and polymicrobial capsules were not achieved.

Original languageEnglish (US)
Pages (from-to)499-508
Number of pages10
JournalJournal of Antimicrobial Chemotherapy
Volume14
Issue number5
DOIs
StatePublished - Nov 1 1984

Fingerprint

Moxalactam
Bacteroides fragilis
Abscess
Escherichia coli
Coinfection
Capsules
Escherichia coli Infections
Animal Models
Bacteria
Serum

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Antimicrobial activity of latamoxef (moxalactam) against both bacteroides fragilis and escherichia coli in an intraperitoneal abscess model. / Harris, Richard W.; Moore, William L.; Arensman, J. Bruce; Rissing, J. Peter.

In: Journal of Antimicrobial Chemotherapy, Vol. 14, No. 5, 01.11.1984, p. 499-508.

Research output: Contribution to journalArticle

@article{2c2704c63e3e4132a8daf45dc3c1ed7d,
title = "Antimicrobial activity of latamoxef (moxalactam) against both bacteroides fragilis and escherichia coli in an intraperitoneal abscess model",
abstract = "The antimicrobial activity of latamoxef (moxalactam) was examined against Bacteroides fragilis and Escherichia coli individually and in combination in an intraperitoneal tissue capsule animal model during ten days of therapy given at 40 mg/kg/day. Mean peak serum concentration was 32.8 mg/1. Mean capsular latamoxef concentrations during samplings on days three, seven and ten were 1.8 mg/1 for Bact. fragilis, 0.7 mg/1 for E. coli, <0.5 mg/1 for polymicrobial infection and 3.4 mg/1 in uninoculated controls. Capsular colony counts for Bact. fragilis and E. coli monomicrobial infections decreased by 2.2 and 4.0 log10 cfu respectively and 1.9 and 3.6 log10 cfu in polymicrobial infections. Latamoxef concentrations necessary to eliminate viable bacteria in both monomicrobial and polymicrobial capsules were not achieved.",
author = "Harris, {Richard W.} and Moore, {William L.} and Arensman, {J. Bruce} and Rissing, {J. Peter}",
year = "1984",
month = "11",
day = "1",
doi = "10.1093/jac/14.5.499",
language = "English (US)",
volume = "14",
pages = "499--508",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Antimicrobial activity of latamoxef (moxalactam) against both bacteroides fragilis and escherichia coli in an intraperitoneal abscess model

AU - Harris, Richard W.

AU - Moore, William L.

AU - Arensman, J. Bruce

AU - Rissing, J. Peter

PY - 1984/11/1

Y1 - 1984/11/1

N2 - The antimicrobial activity of latamoxef (moxalactam) was examined against Bacteroides fragilis and Escherichia coli individually and in combination in an intraperitoneal tissue capsule animal model during ten days of therapy given at 40 mg/kg/day. Mean peak serum concentration was 32.8 mg/1. Mean capsular latamoxef concentrations during samplings on days three, seven and ten were 1.8 mg/1 for Bact. fragilis, 0.7 mg/1 for E. coli, <0.5 mg/1 for polymicrobial infection and 3.4 mg/1 in uninoculated controls. Capsular colony counts for Bact. fragilis and E. coli monomicrobial infections decreased by 2.2 and 4.0 log10 cfu respectively and 1.9 and 3.6 log10 cfu in polymicrobial infections. Latamoxef concentrations necessary to eliminate viable bacteria in both monomicrobial and polymicrobial capsules were not achieved.

AB - The antimicrobial activity of latamoxef (moxalactam) was examined against Bacteroides fragilis and Escherichia coli individually and in combination in an intraperitoneal tissue capsule animal model during ten days of therapy given at 40 mg/kg/day. Mean peak serum concentration was 32.8 mg/1. Mean capsular latamoxef concentrations during samplings on days three, seven and ten were 1.8 mg/1 for Bact. fragilis, 0.7 mg/1 for E. coli, <0.5 mg/1 for polymicrobial infection and 3.4 mg/1 in uninoculated controls. Capsular colony counts for Bact. fragilis and E. coli monomicrobial infections decreased by 2.2 and 4.0 log10 cfu respectively and 1.9 and 3.6 log10 cfu in polymicrobial infections. Latamoxef concentrations necessary to eliminate viable bacteria in both monomicrobial and polymicrobial capsules were not achieved.

UR - http://www.scopus.com/inward/record.url?scp=0021622994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021622994&partnerID=8YFLogxK

U2 - 10.1093/jac/14.5.499

DO - 10.1093/jac/14.5.499

M3 - Article

C2 - 6392279

AN - SCOPUS:0021622994

VL - 14

SP - 499

EP - 508

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 5

ER -